Analysts split on Biogen's potential sale

11/14/2007 | Boston Globe (tiered subscription model), The

A biotech analyst said the potential sale of Biogen Idec to a major drugmaker could reach up to $30 billion if buyers remain positive on the future of its multiple sclerosis drug Tysabri in the market. However, some stock analysts believe the company might not be able to find a buyer due to competition and Biogen's drug-development deals with Elan Corp. and Genentech.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC